Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4426110 | 0.92 | GPR119 (0.53) | GPR119 | |
| SCHEMBL4415809 | 0.92 | GPR119 (0.53) | GPR119 | |
| SCHEMBL4413043 | 0.91 | GPR119 (0.52) | GPR119 | |
| SCHEMBL4413072 | 0.90 | GPR119 (0.51) | GPR119 | |
| SCHEMBL4415897 | 0.90 | GPR119 (0.51) | GPR119 | |
| SCHEMBL4416028 | 0.90 | GPR119 (0.51) | GPR119 | |
| SCHEMBL12548315 | 0.89 | GPR119 (0.57) | GPR119 | |
| SCHEMBL13598250 | 0.88 | GPR119 (0.49) | GPR119 | |
| SCHEMBL13602338 | 0.88 | GPR119 (0.56) | GPR119 | |
| SCHEMBL4419205 | 0.88 | GPR119 (0.54) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018537-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2014-01-16 | — | — | US | disclosed |
| US-8536176-B2 | GPR119 agonist | NIPPON CHEMIPHAR CO., LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| US-20110137032-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| EP-2311822-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2011-04-20 | — | — | EP | disclosed |
| WO-2011025006-A1 | GPR119 AGONIST | 日本ケミファ株式会社 (JP) | 2011-03-03 | — | — | WO | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090325924-A1 | GPCR Agonists | PROSIDION LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| EP-1907383-A1 | GPCR AGONISTS | Prosidion Limited (GB) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007003960-A1 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007003960-A1 | GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325924-A1 | GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885 |
| US-20140018537-A1 | GPR119 AGONIST | GPR119, GPR27, GPR52 | GPR119 1/4885 |
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | GPR119 1/4885 |
| US-20110137032-A1 | GPR119 AGONIST | GPR119, GPR27, GPR52 | GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.